Audiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy

Aim of the work: To evaluate the hearing function in systemic lupus erythematosus (SLE) patients and assess the impact of chronic use of hydroxychloroquine (HCQ). Patients and methods: This study was conducted on 48 SLE patients and 12 matched controls. The SLE disease activity index (SLEDAI) was as...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Samar Tharwat, Wesam Elshawaf, Mohammed Kamal Nassar
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Ototoxicity Systemic lupus erythematosus Hydroxychloroquine Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/df9ad106414b42c582fff27932f3726a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:df9ad106414b42c582fff27932f3726a
record_format	dspace
spelling	oai:doaj.org-article:df9ad106414b42c582fff27932f3726a2021-11-26T04:24:24ZAudiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy1110-116410.1016/j.ejr.2021.08.012https://doaj.org/article/df9ad106414b42c582fff27932f3726a2022-04-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1110116421000879https://doaj.org/toc/1110-1164Aim of the work: To evaluate the hearing function in systemic lupus erythematosus (SLE) patients and assess the impact of chronic use of hydroxychloroquine (HCQ). Patients and methods: This study was conducted on 48 SLE patients and 12 matched controls. The SLE disease activity index (SLEDAI) was assessed. Otological manifestations and extended high frequency audiometry were assessed. SLE patients were divided into those receiving HCQ (n = 36) and those not (n = 12). Results: The mean age of the patients was 39.5 ± 9.7 years, 40 females and 8 males, median disease duration was 7 (1.5–20) years. The median (interquartile range) SLEDAI was 4 (2.75). The median daily dose of those receiving HCQ was 400 mg. There was a significant difference regarding patients reported otological manifestations such as tinnitus (p = 0.02), vertigo (p = 0.002) and hearing impairment (p = 0.04) compared to controls but not for deafness or ear buzzing in one or both ears. There was a significant decrease in the hearing threshold frequencies between patients and controls (p < 0.001). Those receiving HCQ showed more hearing impairment at frequency 9000 and 20,000 Hz than those not (p = 0.004, p < 0.001 respectively). The otological manifestations were comparable between those receiving HCQ and those not. There was no difference between those receiving 400 mg/day (n = 31) HCQ and those receiving 200 mg/day (n = 5) Conclusion: Otological symptoms and sensorineural hearing loss are frequent among SLE patients. Chronic administration of HCQ may have an ototoxic effect.Samar TharwatWesam ElshawafMohammed Kamal NassarElsevierarticleOtotoxicitySystemic lupus erythematosusHydroxychloroquineImmunologic diseases. AllergyRC581-607ENEgyptian Rheumatologist, Vol 44, Iss 2, Pp 171-174 (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ototoxicity Systemic lupus erythematosus Hydroxychloroquine Immunologic diseases. Allergy RC581-607
spellingShingle	Ototoxicity Systemic lupus erythematosus Hydroxychloroquine Immunologic diseases. Allergy RC581-607 Samar Tharwat Wesam Elshawaf Mohammed Kamal Nassar Audiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy
description	Aim of the work: To evaluate the hearing function in systemic lupus erythematosus (SLE) patients and assess the impact of chronic use of hydroxychloroquine (HCQ). Patients and methods: This study was conducted on 48 SLE patients and 12 matched controls. The SLE disease activity index (SLEDAI) was assessed. Otological manifestations and extended high frequency audiometry were assessed. SLE patients were divided into those receiving HCQ (n = 36) and those not (n = 12). Results: The mean age of the patients was 39.5 ± 9.7 years, 40 females and 8 males, median disease duration was 7 (1.5–20) years. The median (interquartile range) SLEDAI was 4 (2.75). The median daily dose of those receiving HCQ was 400 mg. There was a significant difference regarding patients reported otological manifestations such as tinnitus (p = 0.02), vertigo (p = 0.002) and hearing impairment (p = 0.04) compared to controls but not for deafness or ear buzzing in one or both ears. There was a significant decrease in the hearing threshold frequencies between patients and controls (p < 0.001). Those receiving HCQ showed more hearing impairment at frequency 9000 and 20,000 Hz than those not (p = 0.004, p < 0.001 respectively). The otological manifestations were comparable between those receiving HCQ and those not. There was no difference between those receiving 400 mg/day (n = 31) HCQ and those receiving 200 mg/day (n = 5) Conclusion: Otological symptoms and sensorineural hearing loss are frequent among SLE patients. Chronic administration of HCQ may have an ototoxic effect.
format	article
author	Samar Tharwat Wesam Elshawaf Mohammed Kamal Nassar
author_facet	Samar Tharwat Wesam Elshawaf Mohammed Kamal Nassar
author_sort	Samar Tharwat
title	Audiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy
title_short	Audiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy
title_full	Audiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy
title_fullStr	Audiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy
title_full_unstemmed	Audiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy
title_sort	audiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/df9ad106414b42c582fff27932f3726a
work_keys_str_mv	AT samartharwat audiologicevaluationinsystemiclupuserythematosuspatientsandimpactofhydroxychloroquinetherapy AT wesamelshawaf audiologicevaluationinsystemiclupuserythematosuspatientsandimpactofhydroxychloroquinetherapy AT mohammedkamalnassar audiologicevaluationinsystemiclupuserythematosuspatientsandimpactofhydroxychloroquinetherapy
_version_	1718409935265464320

Audiologic evaluation in systemic lupus erythematosus patients and impact of hydroxychloroquine therapy

Ejemplares similares